Sepsis is defined by a rapid transition to systemic immune dysregulation and subsequent multiorgan failure. The absence of spatiotemporally stable blood biomarkers hinders early diagnosis and accurate risk stratification. This study sought to identify robust blood-based molecular markers capable of diagnostic detection and severity stratification across clinical contexts.
The investigators integrated large-scale transcriptomic profiling with supervised machine learning algorithms to screen for diagnostic candidates. The workflow combined differential gene expression analysis and network-based filtering to prioritize genes associated with sepsis. Figures in the original work illustrate correlation heatmaps, principal component analysis, volcano plots of differentially expressed genes, and weighted gene coexpression network analysis (WGCNA) used to identify hub modules correlated with sepsis.
From the integrative multiomics and computational pipeline, a concise three-gene signature emerged: TLR5, HMGB2, and C19orf59. This trio was reported as a robust diagnostic marker set for sepsis. The study emphasized the signature's diagnostic potential when assessed in peripheral blood, forming the core translational claim of the paper.
Single-cell RNA sequencing was used to map the cellular origin of the signature’s upregulation. The authors localized the sepsis-specific increases primarily to the myeloid immune compartment, notably monocytes and neutrophils. This cellular resolution supports a mechanism whereby innate immune cells contribute substantially to the observed circulating transcriptomic signal.
The study examined performance across clinical severity strata using Sequential Organ Failure Assessment (SOFA) score–based grouping. Results reported differential utility among the three genes: TLR5 and HMGB2 performed particularly well in identifying high-risk sepsis patients, whereas C19orf59 maintained consistent diagnostic accuracy across all severity groups. The authors presented these differences as evidence that the panel can contribute both to diagnosis and to severity stratification.
To address potential confounding from surgical or environmental stressors, the investigators used strictly time-matched sham-controlled cecal ligation and puncture (CLP) murine models. In these in vivo experiments, the three-gene signature was found to be persistently upregulated in situ across multiple vital organs (lung, heart, liver) and in systemic circulation, corroborating the blood-based findings and suggesting organ-level involvement of these targets during sepsis.
Complementary in vitro models used lipopolysaccharide (LPS) stimulation to mimic inflammatory activation. These vehicle-controlled experiments characterized temporal expression dynamics of the signature genes. Notably, HMGB2 displayed a biphasic kinetic profile consistent with properties of danger-associated molecular patterns (DAMPs), indicating a potentially distinct mechanistic role in the evolving septic response compared with the other panel members.
The translational relevance of TLR5, HMGB2, and C19orf59 was further tested in an independent cohort of sepsis patient serum samples. The authors reported that serum measurements corroborated the diagnostic potential of the three-gene panel, supporting its applicability beyond discovery datasets and experimental models.
Figures referenced in the manuscript document the study workflow, differential RNA-seq analyses (correlation heatmaps, PCA plots, volcano plots), WGCNA module selection and hub gene screening, and other supporting analyses. The article includes multiple figures illustrating the computational and experimental steps that led to the three-gene signature. Specific dataset identifiers, sample sizes, statistical values, and full numerical results were reported in the original publication; readers should consult the full text for exact quantitative details.
Through a multidimensional evaluation spanning bulk transcriptomics, single-cell RNA sequencing, machine learning, rigorous sham-controlled animal models, controlled in vitro stimulation, and independent clinical serum validation, this study identifies TLR5, HMGB2, and C19orf59 as a concise blood-based diagnostic panel for sepsis. The panel demonstrated both diagnostic robustness and stratification capacity, with TLR5 and HMGB2 highlighting high-risk disease and C19orf59 providing stable performance across severity levels. The work also provides mechanistic insight by localizing expression to myeloid cells and by characterizing a DAMP-like kinetic behavior for HMGB2.
Clinical translation will require further external validation, assay standardization, and prospective evaluation in diverse patient cohorts. The original paper declares no conflicts of interest. For detailed quantitative results, statistical metrics, and dataset specifics, refer to the full published article.